Arvinas to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company specializing in targeted protein degradation, has announced its participation in two upcoming investor conferences:

• The Wells Fargo Healthcare Conference on September 5, 2024, featuring a fireside chat with Ian Taylor, Ph.D., President of R&D, and Randy Teel, Ph.D., Chief Business Officer.
• The Cantor Global Healthcare Conference on September 19, 2024, with Noah Berkowitz, MD, Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, participating in a fireside chat.

Both presentations will be available via live audio webcast on the company's website and through provided links. This engagement with investors highlights Arvinas' commitment to transparency and shareholder communication.

NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:

• Wells Fargo Healthcare Conference on Thursday, September 5, 2024.
  • Ian Taylor, Ph.D., President, R&D, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
    
• Cantor Global Healthcare Conference on Thursday, September 19, 2024.
  • Noah Berkowitz, MD, Ph.D. Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC^® (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Contacts

Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

FAQ

When is Arvinas (ARVN) participating in the Wells Fargo Healthcare Conference?

Arvinas (ARVN) is participating in the Wells Fargo Healthcare Conference on Thursday, September 5, 2024.

Who will represent Arvinas (ARVN) at the Cantor Global Healthcare Conference?

Noah Berkowitz, MD, Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will represent Arvinas (ARVN) at the Cantor Global Healthcare Conference.

Where can investors watch the live webcast of Arvinas' (ARVN) presentations?

Investors can watch the live webcasts of Arvinas' (ARVN) presentations on the Events + Presentations section of the company's website or through the links provided in the announcement.

What type of company is Arvinas (ARVN)?

Arvinas (ARVN) is a clinical-stage biotechnology company that creates a new class of drugs based on targeted protein degradation.